Denali Therapeutics
Stock Forecast, Prediction & Price Target

Denali Therapeutics (DNLI) stock Price Target by analysts

Last Year
Average Price Target

$40

Potential upside: 170.27%

Based on 2 analysts

Denali Therapeutics price prediction

Strike.market

What is Denali Therapeutics stock analysts` prediction?

Denali Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Denali Therapeutics in the last 3 months, the avarage price target is $40, with a high forecast of $NaN. The average price target represents a 170.27% change from the last price of $14.8.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Denali Therapeutics stock Price Target by analysts

Full breakdown of analysts given Denali Therapeutics price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Michael Yee
Jefferies
0%
0/1
10 months ago $45 204.05% upside $27.05 StreetInsider
Previous targets (0)
Thomas Shrader
BTIG
0%
0/1
11 months ago $35 136.48% upside $28 StreetInsider
Previous targets (0)
Tazeen Ahmad
Bank of America Securities
0%
0/1
about 1 year ago $29 95.94% upside $25.12 TheFly
Previous targets (0)
Paul Mattels
Stifel Nicolaus
0%
0/1
about 1 year ago $22 48.64% upside $25.12 StreetInsider
Previous targets (0)
Salveen Richter
Goldman Sachs
0%
0/2
about 1 year ago $46 210.81% upside $25.12 StreetInsider
Previous targets (1)
Marank Mamtani
B.Riley Financial
0%
0/1
about 1 year ago $33 122.97% upside $25.12 StreetInsider
Previous targets (0)
Salveen Richter
Goldman Sachs
0%
0/2
about 4 years ago $112 656.75% upside $52.93 StreetInsider
Previous targets (1)
Esther Rajavelu
UBS
100%
1/1
over 4 years ago $70 372.97% upside $55.51 TheFly
Previous targets (0)

Denali Therapeutics Financial Estimates

Denali Therapeutics Revenue Estimates

Denali Therapeutics EBITDA Estimates

Denali Therapeutics Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$48.66M
 
N/A
$108.46M
 
122.89%
$330.53M
 
204.74%
Avg: $106.65M
Low: $61.83M
High: $216.27M
avg. -67.73%
Avg: $263.82M
Low: $149.30M
High: $505.82M
avg. 147.35%
Avg: $445.38M
Low: $252.05M
High: $853.93M
avg. 68.81%
Avg: $759.60M
Low: $429.87M
High: $1.45B
avg. 70.54%
Net Income
 
% change YoY
$-290.58M
 
N/A
$-325.99M
 
-12.18%
$-145.22M
 
55.45%
Avg: $-464.19M
Low: $-456.07M
High: $-179.95M
avg. -219.64%
Avg: $-394.53M
Low: $-471.18M
High: $-89.29M
avg. 15.00%
Avg: $-129.95M
Low: $-284.91M
High: $-56.62M
avg. 67.06%
Avg: $124.18M
Low: $54.10M
High: $272.27M
avg. 195.56%
EBITDA
 
% change YoY
$-295.75M
 
N/A
$-330.36M
 
-11.70%
$-179.97M
 
45.52%
Avg: $-71.62M
Low: $-145.23M
High: $-41.52M
avg. 60.20%
Avg: $-177.16M
Low: $-339.67M
High: $-100.26M
avg. -147.35%
Avg: $-299.08M
Low: $-573.44M
High: $-169.26M
avg. -68.81%
Avg: $-510.09M
Low: $-978.00M
High: $-288.67M
avg. -70.54%
EPS
 
% change YoY
-$2.39
 
N/A
-$2.6
 
-8.78%
-$1.06
 
59.23%
Avg: -$2.74
Low: -$3.32
High: -$1.31
avg. -158.11%
Avg: -$2.12
Low: -$3.43
High: -$0.65
avg. 22.44%
Avg: -$0.95
Low: -$2.07
High: -$0.41
avg. 55.41%
Avg: $0.9
Low: $0.39
High: $1.98
avg. 195.56%
Operating Expenses
 
% change YoY
$344.41M
 
N/A
$449.20M
 
30.42%
$527.23M
 
17.36%
Avg: $99.03M
Low: $57.41M
High: $200.82M
avg. -81.21%
Avg: $244.98M
Low: $138.63M
High: $469.70M
avg. 147.35%
Avg: $413.57M
Low: $234.05M
High: $792.95M
avg. 68.81%
Avg: $705.35M
Low: $399.17M
High: $1.35B
avg. 70.54%

FAQ

What is Denali Therapeutics stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 14.49% in 2025-2028.

We have gathered data from 12 analysts. Their low estimate is -456.07M, average is -464.19M and high is -179.95M.

What is Denali Therapeutics stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 54.74% in 2025-2028.

We have gathered data from 11 analysts. Their low revenue estimate is $61.83M, average is $106.65M and high is $216.27M.

What is Denali Therapeutics stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 28.82% in 2025-2028.

We have gathered data from 12 analysts. Their low earnings per share estimate is -$3.32, average is -$2.74 and high is $-1.31.

What is the best performing analyst?

In the last twelve months 2 analysts have been covering Denali Therapeutics stock. The most successful analyst is Michael Yee.